Shares of CytomX Therapeutics Inc (NASDAQ:CTMX) have earned an average rating of “Hold” from the fourteen ratings firms that are presently covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $35.29.
A number of equities analysts have issued reports on the stock. BidaskClub raised shares of CytomX Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, December 15th. Cowen reissued an “outperform” rating on shares of CytomX Therapeutics in a report on Thursday, October 5th. Oppenheimer reissued a “hold” rating on shares of CytomX Therapeutics in a report on Wednesday, October 4th. Wedbush set a $37.00 target price on shares of CytomX Therapeutics and gave the stock a “buy” rating in a report on Wednesday, October 4th. Finally, Cantor Fitzgerald started coverage on shares of CytomX Therapeutics in a report on Monday, October 23rd. They issued an “overweight” rating and a $35.00 target price on the stock.
In other news, CEO Sean A. Mccarthy sold 14,342 shares of CytomX Therapeutics stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $19.86, for a total transaction of $284,832.12. Following the sale, the chief executive officer now owns 18,587 shares of the company’s stock, valued at $369,137.82. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Sean A. Mccarthy sold 14,340 shares of CytomX Therapeutics stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $20.60, for a total value of $295,404.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 70,760 shares of company stock worth $1,533,840. Corporate insiders own 4.70% of the company’s stock.
Shares of CytomX Therapeutics (CTMX) traded down $0.06 during midday trading on Friday, reaching $25.73. 411,170 shares of the company’s stock were exchanged, compared to its average volume of 294,117. CytomX Therapeutics has a 1 year low of $11.11 and a 1 year high of $26.58. The company has a market capitalization of $990.56, a PE ratio of -16.18 and a beta of 0.47.
CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.14). CytomX Therapeutics had a negative return on equity of 92.42% and a negative net margin of 113.64%. analysts forecast that CytomX Therapeutics will post -1.58 EPS for the current year.
TRADEMARK VIOLATION WARNING: “CytomX Therapeutics Inc (CTMX) Receives Consensus Recommendation of “Hold” from Brokerages” was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2018/02/11/cytomx-therapeutics-inc-ctmx-receives-consensus-recommendation-of-hold-from-brokerages.html.
About CytomX Therapeutics
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.